Biocept Statistics
Total Valuation
Biocept has a market cap or net worth of 3. The enterprise value is 4.96 million.
| Market Cap | 3 |
| Enterprise Value | 4.96M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Biocept has 2.63 million shares outstanding.
| Shares Outstanding | 2.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +76.47% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 5.15% |
| Float | 2.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.16 |
| EV / Sales | 3.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.27 |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 39.97.
| Current Ratio | 1.81 |
| Quick Ratio | 1.52 |
| Debt / Equity | 39.97 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.63 |
| Interest Coverage | -170.04 |
Financial Efficiency
Return on equity (ROE) is -186.94% and return on invested capital (ROIC) is -72.97%.
| Return on Equity (ROE) | -186.94% |
| Return on Assets (ROA) | -51.65% |
| Return on Capital (ROIC) | -72.97% |
| Revenue Per Employee | 27,140 |
| Profits Per Employee | -612,140 |
| Employee Count | 50 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 11.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.99% in the last 52 weeks. The beta is -18.74, so Biocept's price volatility has been lower than the market average.
| Beta (5Y) | -18.74 |
| 52-Week Price Change | -99.99% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 33.43 |
| Average Volume (20 Days) | 552 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 60.05 |
Income Statement
In the last 12 months, Biocept had revenue of 1.36 million and -30.61 million in losses. Loss per share was -44.33.
| Revenue | 1.36M |
| Gross Profit | -14.30M |
| Operating Income | -33.16M |
| Pretax Income | -30.73M |
| Net Income | -30.61M |
| EBITDA | -31.33M |
| EBIT | -33.16M |
| Loss Per Share | -44.33 |
Balance Sheet
The company has 6.63 million in cash and 11.59 million in debt, giving a net cash position of -4.96 million or -1.89 per share.
| Cash & Cash Equivalents | 6.63M |
| Total Debt | 11.59M |
| Net Cash | -4.96M |
| Net Cash Per Share | -1.89 |
| Equity (Book Value) | 290,000 |
| Book Value Per Share | 0.12 |
| Working Capital | 3.96M |
Cash Flow
In the last 12 months, operating cash flow was -17.60 million and capital expenditures -680,000, giving a free cash flow of -18.28 million.
| Operating Cash Flow | -17.60M |
| Capital Expenditures | -680,000 |
| Free Cash Flow | -18.28M |
| FCF Per Share | -6.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | -2,443.40% |
| Pretax Margin | -2,264.70% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,346.87% |
Dividends & Yields
Biocept does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.55% |
| Shareholder Yield | -25.55% |
| Earnings Yield | -4,432,989,500.00% |
| FCF Yield | -695,994,632.19% |
Stock Splits
The last stock split was on May 17, 2023. It was a reverse split with a ratio of 0.0333333.
| Last Split Date | May 17, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0333333 |
Scores
Biocept has an Altman Z-Score of -23.97. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.97 |
| Piotroski F-Score | n/a |